Plasminogen activator, but not systemic antibiotic therapy, prevents abscess formation in an experimental model of secondary peritonitis

British Journal of Surgery

Volumn 95, Issue 10, 2008, Pages 1287-1293

  Buyne, O R ^a   Bleichrodt, R P ^a   Van Goor, H ^a   Verweij, P E ^a   Hendriks, T ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; CEFTRIAXONE; INTERLEUKIN 10; INTERLEUKIN 6; METRONIDAZOLE; TUMOR NECROSIS FACTOR ALPHA; ANTIINFECTIVE AGENT; FIBRINOLYTIC AGENT; RECOMBINANT PROTEIN; TISSUE PLASMINOGEN ACTIVATOR;

ABDOMINAL ABSCESS; ADJUVANT THERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTEROIDES FRAGILIS; CELL COUNT; CONTROLLED STUDY; DEBRIDEMENT; DRUG EFFECT; ESCHERICHIA COLI; EXPERIMENTAL MODEL; FECES; FIBRINOLYTIC THERAPY; INFLAMMATION; INJECTION; NONHUMAN; PERITONEAL FLUID; PERITONITIS; PRIORITY JOURNAL; RAT; WISTAR RAT; ANIMAL; MALE;

ABDOMINAL ABSCESS; ANIMALS; ANTI-BACTERIAL AGENTS; CEFTRIAXONE; DEBRIDEMENT; FIBRINOLYTIC AGENTS; MALE; METRONIDAZOLE; PERITONITIS; RATS; RATS, WISTAR; RECOMBINANT PROTEINS; TISSUE PLASMINOGEN ACTIVATOR;

EID: 52449085504     PISSN: 00071323     EISSN: 13652168     Source Type: Journal    
DOI: 10.1002/bjs.6309     Document Type: Article

References (35)

1. Sihler KC, Nathens AB. Management of severe sepsis in the surgical patient. Surg Clin North Am 2006; 86: 1457-1481.
2. Gullo A, Bianco N, Berlot G. Management of severe sepsis and septic shock: challenges and recommendations. Crit Care Clin 2006; 22: 489-501, ix.
3. Lamme B, Boermeester MA, Reitsma JB, Mahler CW, Obertop H, Gouma DJ. Meta-analysis of relaparotomy for secondary peritonitis. Br J Surg 2002; 89: 1516-1524.
4. Wittmann DH, Schein M, Condon RE. Management of secondary peritonitis. Ann Surg 1996; 224: 10-18.
5. Emmanuel K, Weighardt H, Bartels H, Siewert JR, Holzmann B. Current and future concepts of abdominal sepsis. World J Surg 2005; 29: 3-9.
6. van Ruler O, Mahler CW, Boer KR, Reuland EA, Gooszen HG, Opmeer BC et al. Comparison of on-demand vs planned relaparotomy strategy in patients with severe peritonitis: a randomized trial. JAMA 2007; 298: 865-872.
7. Marshall JC, Innes M. Intensive care unit management of intra-abdominal infection. Crit Care Med 2003; 31: 2228-2237.
8. Holmdahl L. The role of fibrinolysis in adhesion formation. Eur J Surg Suppl 1997; 577: 24-31.
9. Holmdahl L, Falkenberg M, Ivarsson ML, Risberg B. Plasminogen activators and inhibitors in peritoneal tissue. APMIS 1997; 105: 25-30.
10. van Veen SQ, Levi M, van Vliet AK, Florquin S, van Gulik TM, Boermeester MA. Peritoneal lavage with activated protein C alters compartmentalized coagulation and fibrinolysis and improves survival in polymicrobial peritonitis. Crit Care Med 2006; 34: 2799-2805.
11. Rotstein OD, Kao J. Prevention of intra-abdominal abscesses by fibrinolysis using recombinant tissue plasminogen activator. J Infect Dis 1988; 158: 766-772.
12. van Goor H, de Graaf JS, Kooi K, Sluiter WJ, Bom VJ, van der Meer J et al. Effect of recombinant tissue plasminogen activator on intra-abdominal abscess formation in rats with generalized peritonitis. J Am Coll Surg 1994; 179: 407-411.
13. van Goor H, de Graaf JS, Kooi K, Bleichrodt RP. Gentamycin reduces bacteremia and mortality rates associated with the treatment of experimental peritonitis with recombinant tissue plasminogen activator. J Am Coll Surg 1995; 181: 38-42.
14. Buyne OR, Bleichrodt RP, van Goor H, Verweij PE, Hendriks T. Tissue-type plasminogen activator prevents formation of intra-abdominal abscesses after surgical treatment of secondary peritonitis in a rat model. Int J Colorectal Dis 2007; 22: 819-825.
15. Boermeester MA. Surgical approaches to peritonitis. Br J Surg 2007; 94: 1317-1318.
16. Buyne OR, Bleichrodt RP, Verweij PE, Groenewoud HM, van Goor H, Hendriks T. A peritonitis model with low mortality and persisting intra-abdominal abscesses. Int J Exp Pathol 2006; 87: 361-368.
17. Buyne OR, Bleichrodt RP, van Goor H, Verweij PE, Hendriks T. Both tissue-type plasminogen activator and urokinase prevent intra-abdominal abscess formation after surgical treatment of peritonitis in the rat. Surgery 2008; 144: 66-73.
18. Collen D, Lijnen HR. Thrombolytic agents. Thromb Haemost 2005; 93: 627-630.
19. Reijnen MM, Bleichrodt RP, van Goor H. Pathophysiology of intra-abdominal adhesion and abscess formation, and the effect of hyaluronan. Br J Surg 2003; 90: 533-541.
20. Tarhan OR, Barut I, Sezik M. An evaluation of normal saline and taurolidine on intra-abdominal adhesion formation and peritoneal fibrinolysis. J Surg Res 2008; 144: 151-157.
21. Deitcher SR Jaff MR. Pharmacologic and clinical characteristics of thrombolytic agents. Rev Cardiovasc Med 2003; 3(Suppl 2): S25-S33.
22. van Goor H. In vitro studies on the effect of recombinant tissue plasminogen activator on the rat fibrinolytic system. In Fibrinolytic Therapy in Generalized Peritonitis to Prevent Intraabdominal Abscess Formation (Thesis). Radboud University: Nijmegen, 1996; 125-134.
23. Raptopoulos V, Gourtsoyiannis N. Peritoneal carcinomatosis. Eur Radiol 2001; 11: 2195-2206.
24. Schein M. Surgical management of intra-abdominal infection: is there any evidence? Langenbecks Arch Surg 2002; 387: 1-7.
25. Tomita H, Osada S, Miya K, Matsuo M. Delayed recurrence of postoperative intra-abdominal abscess: an unusual case and review of the literature. Surg Infect (Larchmt) 2006; 7: 551-554.
26. van Till JW, Lamme B, van Esch TJ, van der Poll T, van Gulik TM, Boermeester MA. Surgical therapy attenuates abdominal and extra-abdominal inflammation in experimental peritonitis. Eur Surg Res 2006; 38: 76-82.
27. Wong PF, Gilliam AD, Kumar S, Shenfine J, O'Dair GN, Leaper DJ. Antibiotic regimens for secondary peritonitis of gastrointestinal origin in adults. Cochrane Database Syst Rev 2005; (2)CD004539.
28. Orozco H, Arch J, Medina-Franco H, Pantoja JP, Gonzalez QH, Vilatoba M et al. Molgramostim (GM-CSF) associated with antibiotic treatment in nontraumatic abdominal sepsis: a randomized, double-blind, placebo-controlled clinical trial. Arch Surg 2006; 141: 150-153.
29. Turnbull IR, WlzorekJJ, Osborne D, Hotchkiss RS, Coopersmith CM, Buchman TG. Effects of age on mortality and antibiotic efficacy in cecal ligation and puncture. Shock 2003; 19: 310-313.
30. Bauhofer A, Torossian A, Lorenz W, Middeke M, Plaul U, Schutz P et al. Dependence of positive effects of granulocyte colony-stimulating factor on the antibiotic regimen: evaluation in rats with polymicrobial peritonitis. World J Surg 2004; 28: 834-844.
31. Wagner C, Sauermann R, Joukhadar C. Principles of antibiotic penetration into abscess fluid. Pharmacology 2006; 78: 1-10.
32. Renckens R, Roelofs JJ, Florquin S, de Vos AF, Pater JM, Lijnen HR et al. Endogenous tissue-type plasminogen activator is protective during Escherichia coli-induced abdominal sepsis in mice. J Immunol 2006; 177: 1189-1196.
33. Roelofs JJ, Rouschop KM, Teske GJ, Ciaessen N, Weening JJ, van der Poll T et al. The urokinase plasminogen activator receptor is crucially involved in host defense during acute pyelonephritis. Kidney Int 2006; 70: 1942-1947.
34. van Veen SQ, Meijers JC, Levi M, van Gulik TM, Boermeester MA. Effects of intra-abdominal administration of recombinant tissue plasminogen activator on coagulation, fibrinolysis and inflammatory responses in experimental polymicrobial peritonitis. Shock 2007; 27: 534-541.
35. Cook AD, Vlahos R, Massa CM, Braine EL, Lenzo JC, Turner AL et al. The effect of tissue type-plasminogen activator deletion and associated fibrin(ogen) deposition on macrophage localization in peritoneal inflammation. Thromb Haemost 2006; 95: 659-667.